RS61418B1 - Kompozicije glikopeptida - Google Patents

Kompozicije glikopeptida

Info

Publication number
RS61418B1
RS61418B1 RS20210108A RSP20210108A RS61418B1 RS 61418 B1 RS61418 B1 RS 61418B1 RS 20210108 A RS20210108 A RS 20210108A RS P20210108 A RSP20210108 A RS P20210108A RS 61418 B1 RS61418 B1 RS 61418B1
Authority
RS
Serbia
Prior art keywords
glycopeptide compositions
glycopeptide
compositions
Prior art date
Application number
RS20210108A
Other languages
English (en)
Inventor
Ivona Jasprica
Sabina Keser
Katarina Pindric
Original Assignee
Xellia Pharmaceuticals Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54478023&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS61418(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Xellia Pharmaceuticals Aps filed Critical Xellia Pharmaceuticals Aps
Publication of RS61418B1 publication Critical patent/RS61418B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
RS20210108A 2014-11-06 2015-11-06 Kompozicije glikopeptida RS61418B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462076400P 2014-11-06 2014-11-06
US201562168749P 2015-05-30 2015-05-30
EP19174849.0A EP3542812B1 (en) 2014-11-06 2015-11-06 Glycopeptide compositions

Publications (1)

Publication Number Publication Date
RS61418B1 true RS61418B1 (sr) 2021-03-31

Family

ID=54478023

Family Applications (2)

Application Number Title Priority Date Filing Date
RS20200080A RS59851B1 (sr) 2014-11-06 2015-11-06 Kompozicije glikopeptida
RS20210108A RS61418B1 (sr) 2014-11-06 2015-11-06 Kompozicije glikopeptida

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RS20200080A RS59851B1 (sr) 2014-11-06 2015-11-06 Kompozicije glikopeptida

Country Status (30)

Country Link
US (7) US10188697B2 (sr)
EP (4) EP3542812B1 (sr)
JP (2) JP6797795B2 (sr)
KR (2) KR102603756B1 (sr)
CN (1) CN107073072B (sr)
AU (1) AU2015341763B2 (sr)
BR (1) BR112017009405B1 (sr)
CA (1) CA2964524A1 (sr)
CL (1) CL2017001139A1 (sr)
CO (1) CO2017005391A2 (sr)
CR (1) CR20170234A (sr)
CY (2) CY1122960T1 (sr)
DK (2) DK3215173T3 (sr)
EA (1) EA035368B1 (sr)
ES (2) ES2852550T3 (sr)
HR (2) HRP20200101T1 (sr)
HU (2) HUE053347T2 (sr)
IL (1) IL252120B (sr)
MX (1) MX2017005749A (sr)
NZ (1) NZ731955A (sr)
PH (1) PH12017500720A1 (sr)
PL (2) PL3542812T3 (sr)
PT (2) PT3542812T (sr)
RS (2) RS59851B1 (sr)
SA (1) SA517381446B1 (sr)
SG (1) SG11201703568WA (sr)
SI (2) SI3215173T1 (sr)
TN (1) TN2017000182A1 (sr)
WO (1) WO2016071495A1 (sr)
ZA (1) ZA201702767B (sr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102603756B1 (ko) 2014-11-06 2023-11-16 셀리아 파마슈티칼즈 에이피에스 글리코펩티드 조성물
WO2017111601A1 (en) * 2015-12-24 2017-06-29 Universiteit Leiden Composition and method for treating infections caused by vancomycin-resistant infectious agents in a subject
CN109069580A (zh) * 2016-05-09 2018-12-21 埃克斯利亚制药有限公司 稳定化的糖肽抗生素配制品
RU2019119405A (ru) * 2016-11-23 2020-12-25 Гуфик Байосайенсиз Лимитед Лиофилизированные фармацевтические композиции далбаванцина
JP7118412B2 (ja) * 2017-07-31 2022-08-16 東洋製薬化成株式会社 バンコマイシン懸濁液充填カプセル製剤
CN109725101B (zh) * 2017-10-31 2021-11-19 正大天晴药业集团股份有限公司 盐酸特拉万星原料中有关物质的检测方法
CN109078001B (zh) * 2018-09-21 2021-05-07 深圳浦瑞健康科技有限公司 一种万古霉素纳米脂质体组合物及其制备方法
CA3132923A1 (en) 2019-03-08 2020-09-17 Emphascience, Inc. Stable pharmaceutical formulations of peptide and protein drugs
US11433115B2 (en) * 2020-10-30 2022-09-06 Somerset Therapeutics, Llc Glycopeptide antibiotics liquid formulations and methods and uses thereof
EP4014965A1 (en) 2020-12-16 2022-06-22 EVER Valinject GmbH Aqueous solution
EP4014969A1 (en) * 2020-12-16 2022-06-22 EVER Valinject GmbH Aqueous solution
WO2022234036A1 (en) * 2021-05-07 2022-11-10 Xellia Pharmaceuticals Aps Oral liquid vancomycin formulations
CN115804832A (zh) * 2021-09-14 2023-03-17 海南普利制药股份有限公司 一种万古霉素水溶液组合物
WO2023171588A1 (ja) * 2022-03-08 2023-09-14 国立大学法人大阪大学 抗菌薬を含有するｐｌｇａ製剤
GB202207345D0 (en) 2022-05-19 2022-07-06 Arecor Ltd Novel composition
GB202207344D0 (en) 2022-05-19 2022-07-06 Arecor Ltd Novel composition
US20240139282A1 (en) * 2022-10-12 2024-05-02 Xellia Pharmaceuticals Aps Liquid dalbavancin compositions
WO2024079224A1 (en) * 2022-10-12 2024-04-18 Xellia Pharmaceuticals Aps Liquid dalbavancin composition

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4670258A (en) 1984-02-10 1987-06-02 Vanderbilt University Storable prepackaged aqueous solutions of vancomycin
UA43323C2 (uk) 1994-01-28 2001-12-17 Елі Ліллі Енд Компані Антибіотичні похідні глікопептидів, спосіб отримання та фармацевтична композиція
AU1407197A (en) 1995-12-01 1997-06-19 Eli Lilly And Company Stable vancomycin hydrochloride solutions
JPH1180021A (ja) 1997-09-02 1999-03-23 Kayaku:Kk バンコマイシン注射剤
US6800608B2 (en) 2001-06-22 2004-10-05 Beckman Coulter, Inc. Homogeneous assay of vancomycin using a stable particle-vancomycin conjugate, a novel rate enhancer, and a novel dose response modulator
US7022712B2 (en) * 2002-03-26 2006-04-04 Arizona Board Of Regents On Behalf Of The University Of Arizona Solubilization of weak bases
GB0212622D0 (en) * 2002-05-31 2002-07-10 Natural Technologies Group Ltd Bacterial transforming agent
CN1802090A (zh) * 2002-07-09 2006-07-12 尖端医疗有限公司 硼脯氨酸化合物组合治疗
AU2003248921A1 (en) 2002-07-09 2004-01-23 Point Therapeutics, Inc. Boroproline compound combination therapy
EP1565201B1 (en) 2002-11-18 2018-10-31 Vicuron Pharmaceuticals, Inc. Methods of administering dalbavancin for treatment of bacterial infections
AU2006213441B2 (en) 2005-02-14 2011-12-01 Venus Remedies Limited Parenteral combination therpy for infective conditions with drug resistant bacterium
CN1857716A (zh) * 2006-03-14 2006-11-08 浙江大学 注射用盐酸万古霉素及其制备方法
JP2008201778A (ja) 2007-01-25 2008-09-04 Mochida Pharmaceut Co Ltd バンコマイシン液状製剤
CN102026666B (zh) * 2007-12-11 2013-10-16 常山凯捷健生物药物研发（河北）有限公司 促胰岛素肽缀合物制剂
JP2011080021A (ja) 2009-10-09 2011-04-21 Bridgestone Corp 熱可塑性エラストマー組成物及びその成形体
CA2981038C (en) * 2011-05-19 2018-09-25 Savara Inc. Dry powder vancomycin compositions and associated methods
US20150182667A1 (en) 2012-08-08 2015-07-02 Vanderbilt University Composition with Biofilm Dispersal Agents
RU2018135921A (ru) * 2012-11-29 2019-02-05 Инсмед Инкорпорейтед Стабилизированные составы ванкомицина
CN104043104B (zh) 2013-03-15 2018-07-10 浙江创新生物有限公司 含盐酸万古霉素的喷雾干粉及其工业化制备方法
WO2014194296A1 (en) 2013-05-30 2014-12-04 Scidose, Llc Formulations of vancomycin
US10959946B2 (en) 2014-03-14 2021-03-30 Azurity Pharmaceuticals, Inc. Composition and method for vancomycin oral liquid
KR102603756B1 (ko) * 2014-11-06 2023-11-16 셀리아 파마슈티칼즈 에이피에스 글리코펩티드 조성물
CN109069580A (zh) 2016-05-09 2018-12-21 埃克斯利亚制药有限公司 稳定化的糖肽抗生素配制品
US11433115B2 (en) 2020-10-30 2022-09-06 Somerset Therapeutics, Llc Glycopeptide antibiotics liquid formulations and methods and uses thereof
EP4014965A1 (en) 2020-12-16 2022-06-22 EVER Valinject GmbH Aqueous solution
EP4014969A1 (en) 2020-12-16 2022-06-22 EVER Valinject GmbH Aqueous solution

Also Published As

Publication number Publication date
PL3215173T3 (pl) 2020-05-18
US10039804B2 (en) 2018-08-07
US20190160142A1 (en) 2019-05-30
DK3215173T3 (da) 2020-03-23
JP2020183424A (ja) 2020-11-12
BR112017009405B1 (pt) 2024-02-06
AU2015341763A1 (en) 2017-06-08
EA035368B1 (ru) 2020-06-03
HUE049857T2 (hu) 2020-10-28
US10188697B2 (en) 2019-01-29
CY1122960T1 (el) 2021-10-29
US11628200B2 (en) 2023-04-18
EP3215173B8 (en) 2020-03-11
CL2017001139A1 (es) 2017-12-01
US20210220433A1 (en) 2021-07-22
PT3215173T (pt) 2020-04-03
CN107073072B (zh) 2021-06-18
US11000567B2 (en) 2021-05-11
AU2015341763B2 (en) 2019-01-17
EA201790997A1 (ru) 2017-09-29
KR20230096142A (ko) 2023-06-29
ES2769849T3 (es) 2020-06-29
PL3542812T3 (pl) 2021-07-12
PT3542812T (pt) 2021-04-20
US20220354927A1 (en) 2022-11-10
JP6797795B2 (ja) 2020-12-09
HUE053347T2 (hu) 2021-06-28
TN2017000182A1 (en) 2018-10-19
MX2017005749A (es) 2018-01-11
ZA201702767B (en) 2018-12-19
DK3542812T3 (da) 2021-04-12
SI3215173T1 (sl) 2020-03-31
JP7032488B2 (ja) 2022-03-08
EP4147710A1 (en) 2023-03-15
JP2017533218A (ja) 2017-11-09
HRP20210342T1 (hr) 2021-04-30
US20230158101A1 (en) 2023-05-25
KR20170078830A (ko) 2017-07-07
SI3542812T1 (sl) 2021-04-30
KR102603756B1 (ko) 2023-11-16
SA517381446B1 (ar) 2020-09-21
IL252120A0 (en) 2017-07-31
PH12017500720A1 (en) 2017-10-09
EP3215173B1 (en) 2020-01-01
US20170348385A1 (en) 2017-12-07
CR20170234A (es) 2018-01-15
US20180133286A1 (en) 2018-05-17
IL252120B (en) 2020-07-30
SG11201703568WA (en) 2017-05-30
HRP20200101T1 (hr) 2020-04-03
ES2852550T3 (es) 2021-09-13
CA2964524A1 (en) 2016-05-12
CY1124011T1 (el) 2022-05-27
NZ731955A (en) 2023-07-28
CO2017005391A2 (es) 2017-10-31
EP3215173A1 (en) 2017-09-13
BR112017009405A2 (pt) 2018-01-02
US11517609B2 (en) 2022-12-06
HRP20210342T8 (hr) 2022-01-21
RS59851B1 (sr) 2020-02-28
EP3834837A1 (en) 2021-06-16
US20200069768A1 (en) 2020-03-05
EP3542812B1 (en) 2021-01-13
US10849956B2 (en) 2020-12-01
CN107073072A (zh) 2017-08-18
EP3542812A1 (en) 2019-09-25
WO2016071495A1 (en) 2016-05-12

Similar Documents

Publication Publication Date Title
HRP20210342T8 (hr) Pripravci glikopeptida
SG11201705415YA (en) Multi-supplement compositions
IL257131A (en) Preparations
HK1251559A1 (zh) 普那布林組合物
GB201501598D0 (en) Compositions
GB201515387D0 (en) Compositions
GB201515391D0 (en) Compositions
SI3349766T1 (sl) Antihemoragični sestavki
IL251479B (en) components
GB201408167D0 (en) Compositions
GB201420306D0 (en) Compositions
GB2538335B (en) Compositions
PL3393503T3 (pl) Kompozycje
GB201522892D0 (en) Compositions
GB201511469D0 (en) Compositions
GB201507673D0 (en) Compositions
GB201504995D0 (en) Compositions
GB201504045D0 (en) Compositions
GB201419849D0 (en) Compositions
GB201406863D0 (en) Compositions comprising variegin